SGX Market Updates

SGX Listed Medical Suppliers Continued to Trade Actively in January 2021


PUBLISHED ON |

02 February 2021

  • In January, the iEdge SG All Healthcare Index generated a 4% return, following a 4% decline in 4th quarter of 2020 and 77% total return over the first 3 quarters of 2020. Following the last rebalance, the largest weights of the Index are Haw Par, Raffles Medical, Parkway Life REIT, IHH Healthcare and Top Glove.

  • In 2020, Medtecs International, Top Glove, Riverstone and UG Healthcare ranked among top 50 stocks by turnover, and continued to be so ranked in early 2021. In 2020, the 4 stocks contributed a combined S$42 million a day in daily turnover, with indications half of that turnover was generated by retail investors.

  • Retail investors also appear to have contributed to just over half the combined daily trading activity of Medtecs International, Top Glove, Riverstone and UG Healthcare in January 2021. These stocks averaged 18% returns for the month, with Riverstone and UG Healthcare the strongest performers of the iEdge SG All Healthcare Index in January.




The broking industry has seen a resurgence of retail trading activity amid the broad market volatility that has seen significant trading ranges over the past 12 months. Keeping in mind the old adage of when stocks move, traders react, when stocks don’t move, traders tend to stay on the sidelines, in 2020, the Straits Times Index (“STI”) established its biggest trading range for a year since 2009.

Moreover, the trading range of the iEdge SG All Healthcare Index in 2020 was a remarkable 150% between low to high, 15 times the Index range of the preceding 5 years. The social and economic impacts of the Coronavirus have been the overarching market driver for the broader stock market, with measured impacts on particular industries such as medical supplies. This means the market drivers of the big movers of the iEdge SG All Healthcare Index have made the headlines almost every day.

The constituents of the iEdge SG All Healthcare Index averaged S$63 million in daily turnover in 2020, with S$52 million in daily turnover in January 2021. The undermentioned medical suppliers comprised two-thirds of the combined Index turnover in both 2020 and January 2021.

During 2020, Medtecs International (SGX:546), Top Glove (SGX:BVA), Riverstone (SGX:AP4) and UG Healthcare (SGX:8L7) were among the top 50 stocks by turnover, with this segment remaining so in early 2021. In 2020, these 4 stocks contributed a combined S$42 million a day in daily turnover, with anecdotal evidence suggesting that half of that turnover was contributed by retail investors. At the same time net retail inflows into the 4 stocks for the entire 2020 year was close to S$150 million, which was 0.9% of their combined end of year market value. Indications are that retail investors have also contributed just over 50% to the combined S$34 million average daily turnover of these stocks in January 2021.


The recent performance of the 20 most traded constituents of the iEdge SG All Healthcare Index stocks in January 2021 are tabled below.

20 Most Traded Stocks of
iEdge SG All Healthcare Index
in Jan 2021
SGX
Code
Market
Cap
S$m
Average
Daily Turnover
in 2020
S$M
Net Retail
Inflow
in 2020
S$M
2020
Total Return
%
Average
Daily Turnover
in Jan 2021
S$M
Net Retail
Inflow
in Jan 2021
S$M
Jan 2021
Total Return
%
Medtecs International 546 571 20.08 -12.5 2,628 10.33 7.13 4
Top Glove BVA 17,491 6.08 118.7 300 10.08 14.32 9
Riverstone AP4 2,223 9.14 42.8 143 8.62 -10.06 35
UG Healthcare 8K7 447 7.00 18.8 1,157 5.27 -0.30 24
Singapore Medical Group 5OT 181 0.46 9.0 8 2.92 -1.72 17
First REIT AW9U 185 1.72 40.4 -75 2.44 0.62 3
Parkway Life REIT C2PU 2,511 3.24 7.9 21 2.35 -3.40 7
Vicplas International 569 138 2.38 -0.7 169 2.22 0.40 10
Q&M Dental Group QC7 346 0.40 -4.9 3 1.64 -8.18 -6
Haw Par Corp H02 2,477 1.65 43.8 -14 1.39 -2.87 5
Raffles Medical Group BSL 1,743 1.43 1.5 3 1.39 5.01 -6
iX Biopharma 42C 181 1.34 2.2 13 0.69 -0.93 2
Biolidics 8YY 81 2.46 4.6 22 0.65 -0.10 2
Clearbridge Health 1H3 94 1.86 1.4 7 0.47 -0.35 4
Tianjin Zhong Xin Pharmaceutical T14 2,270 0.49 10.5 7 0.35 0.72 -1
Nutryfarm International AZT 49 0.03 0.8 340 0.35 0.57 15
Thomson Medical Group A50 1,296 0.43 -4.4 -22 0.30 0.96 -2
Hyphens Pharma International 1J5 96 1.51 6.3 56 0.22 0.18 2
Singapore O&G 1D8 119 0.05 1.1 -20 0.10 -0.14 6
Asian Healthcare Specialists 1J3 89 0.28 5.1 -13 0.09 -0.04 6
Median 11 4
Average 237 7

Source: SGX StockFacts, Refinitiv and Bloomberg (Data as of 31 January 2021)



During the past year, retail investors were able to access company financial statements, outlooks, corporate presentations and broker research.

  • In September, Top Glove (SGX:BVA) reported a 418% increase in its FY20 (ended 31 August) net profit, which paralleled the stocks 447% price gain over the period (click here for more). For its 1QFY21, Top Glove reported its y-o-y net profit was up just over 20-fold (click here for more).

  • Similarly, in October, Medtecs International (SGX:546) updated that its 9MFY20 (ended 30 September) net profit had grown close to 200-fold y-o-y (click here for more), which coincided with its share price soaring close to 30-fold from 3.7 cents to S$1.08.

  • Riverstone (SGX:AP4) updated that its 9MFY20 (ended 30 Sep) net profit was up just over 220% y-o-y (click here for more), while its stock price was up 277%.

  • Meanwhile Catalist-listed UG Healthcare (SGX:447) reported its net profit for FY20 (ended 30 June) was up more than five-fold (click here for more), and 1QFY21 (ended 30 Sep) attributable net profit was up more than 70-fold (click here for more).



Riverstone was the strongest performer of the iEdge SG All Healthcare Index constituents in January 2021.

On 1 December, the Employees Provident Fund Board of Malaysia (“EPF”) increased its substantial shareholder of Riverstone to above the 7.00 per cent threshold. This followed on from a filing on 26 October that reported the EPF increased its substantial shareholder above the 6.00 per cent threshold, after the EPF became a substantial shareholder of Riverstone on 17 September.

The company noted back on 9 November that Phase 6 of the Group’s expansion plans is on track to raise total production capacity by 1.5 billion pieces to 10.5 billion pieces of gloves annually by the end of 2020. For phase 6, the Group noted it had commissioned five production lines that are currently in operation, with the remaining two production lines progressively commissioned over the next two months. Furthermore, due to the strong demand for both healthcare and cleanroom gloves, Riverstone’s current order book has been filled to the first half of 2021.



Recent Growth in Retail Trading

While financials and outlooks can drive investor interest, investors are always encouraged to seek checks and balances. Incorporating fundamentals with prices, to generate valuations can help provide checks, while avoiding concentrating too much portfolio exposure to one stock or asset can provide the balances.

Recent years have also seen technology emerge as a key enabler for access to markets, in addition to data, information, research and education. For its 1HFY20 (ended 30 June), UOB-Kay Hian (SGX:U10) reported that commission income had increased 90% mainly due to active retail participation across regional and US markets as a result of market volatility, and in October, when iFAST Corporation (SGX:AIY) reported its 9MFY20 (ended 30 September) results, the group highlighted that improvement in the business showed iFAST Corp continued to be a beneficiary of increased digital adoption in the wealth management industry.

Increased digitalisation of financial services bodes well for the organic growth of retail investing, supported by adequately capitalised brokers that manage their value at risk, publish research and provide advice in-line with their regulatory requirements. Another consequence of the growth in retail investing is new and fast flows that as seen in the United States last week can impact the market risk that short-sellers face.

The strong aforementioned retail trading interest in the medical suppliers compared to indications retail investors contributed less than a fifth to the daily turnover of the DBS, OCBC and UOB in 2020, with net retail inflows making up 2.2% of their combined market value. Note that while the three banks attracted significant institutional trading with their heavyweight representation in the local and regional indices, retail activity extended to regular share saving plans, which are dollar cost averaging methods followed by 60,000 retail investors, in addition to significant turnover and inflows into the STI ETFs.

Singapore Exchange also lists for trading a number of leveraged security and derivative products that are designed to cater to increased risk appetites by retail investors, which are firstly categorised as Specified Investor Products and secondly utilise margining that is in-line with the best industry standards.







This article is provided by SGX My Gateway.



SGX My Gateway

SGX's investor education portal with market, product and investment information and events. Sign up now at sgx.com/mygateway to receive our investment updates and economic calendar.

This document is not intended for distribution to, or for use by or to be acted on by any person or entity located in any jurisdiction where such distribution, use or action would be contrary to applicable laws or regulations or would subject Singapore Exchange Limited (“SGX”) to any registration or licensing requirement. This document is not an offer or solicitation to buy or sell, nor financial advice or recommendation for any investment product. This document is for general circulation only. It does not address the specific investment objectives, financial situation or particular needs of any person. Advice should be sought from a financial adviser regarding the suitability of any investment product before investing or adopting any investment strategies. Use of and/or reliance on this document is entirely at the reader’s own risk. Further information on this investment product may be obtained from www.sgx.com. Investment products are subject to significant investment risks, including the possible loss of the principal amount invested. Past performance of investment products is not indicative of their future performance. Examples provided are for illustrative purposes only. While each of SGX and its affiliates (collectively, the SGX Group Companies) have taken reasonable care to ensure the accuracy and completeness of the information provided, each of the SGX Group Companies disclaims any and all guarantees, representations and warranties, expressed or implied, in relation to this document and shall not be responsible or liable (whether under contract, tort (including negligence) or otherwise) for any loss or damage of any kind (whether direct, indirect or consequential losses or other economic loss of any kind, including without limitation loss of profit, loss of reputation and loss of opportunity) suffered or incurred by any person due to any omission, error, inaccuracy, incompleteness, or otherwise, any reliance on such information, or arising from and/or in connection with this document. The information in this document may have been obtained via third party sources and which have not been independently verified by any SGX Group Company. No SGX Group Company endorses or shall be liable for the content of information provided by third parties. The SGX Group Companies may deal in investment products in the usual course of their business, and may be on the opposite side of any trades. SGX is an exempt financial adviser under the Financial Advisers Act (Cap. 110) of Singapore. The information in this document is subject to change without notice. This document shall not be reproduced, republished, uploaded, linked, posted, transmitted, adapted, copied, translated, modified, edited or otherwise displayed or distributed in any manner without SGX’s prior written consent.












Stock / REIT Search

Advertisement

Advertisement